Nls Pharmaceutics Ag Stock Performance
| NLSP Stock | USD 1.51 0.01 0.67% |
The company secures a Beta (Market Risk) of -0.22, which conveys not very significant fluctuations relative to the market. As returns on the market increase, returns on owning NLS Pharmaceutics are expected to decrease at a much lower rate. During the bear market, NLS Pharmaceutics is likely to outperform the market. NLS Pharmaceutics currently secures a risk of 10.27%. Please verify NLS Pharmaceutics AG downside variance, as well as the relationship between the daily balance of power and relative strength index , to decide if NLS Pharmaceutics AG will be following its current price movements.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days NLS Pharmaceutics AG has generated negative risk-adjusted returns adding no value to investors with long positions. Even with relatively invariable basic indicators, NLS Pharmaceutics is not utilizing all of its potentials. The recent stock price agitation, may contribute to short-term losses for the retail investors. ...more
| Begin Period Cash Flow | 8.9 M |
NLS |
NLS Pharmaceutics Relative Risk vs. Return Landscape
If you would invest 198.00 in NLS Pharmaceutics AG on December 23, 2024 and sell it today you would lose (47.00) from holding NLS Pharmaceutics AG or give up 23.74% of portfolio value over 90 days. NLS Pharmaceutics AG is currently generating 0.0052% in daily expected returns and assumes 10.271% risk (volatility on return distribution) over the 90 days horizon. In different words, 91% of stocks are less volatile than NLS, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
NLS Pharmaceutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for NLS Pharmaceutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as NLS Pharmaceutics AG, and traders can use it to determine the average amount a NLS Pharmaceutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 5.0E-4
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | NLSP |
Estimated Market Risk
| 10.27 actual daily | 91 91% of assets are less volatile |
Expected Return
| 0.01 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| 0.0 actual daily | 0 Most of other assets perform better |
Based on monthly moving average NLS Pharmaceutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of NLS Pharmaceutics by adding NLS Pharmaceutics to a well-diversified portfolio.
NLS Pharmaceutics Fundamentals Growth
NLS Stock prices reflect investors' perceptions of the future prospects and financial health of NLS Pharmaceutics, and NLS Pharmaceutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on NLS Stock performance.
| Return On Equity | -8.63 | ||||
| Return On Asset | -2.28 | ||||
| Current Valuation | 7.29 M | ||||
| Shares Outstanding | 4.06 M | ||||
| Price To Book | 4.84 X | ||||
| EBITDA | (11.8 M) | ||||
| Cash And Equivalents | 1.35 M | ||||
| Cash Per Share | 0.08 X | ||||
| Total Debt | 1.63 M | ||||
| Book Value Per Share | (9.40) X | ||||
| Cash Flow From Operations | (9.68 M) | ||||
| Earnings Per Share | (6.74) X | ||||
| Total Asset | 1.85 M | ||||
| Retained Earnings | (70.37 M) | ||||
About NLS Pharmaceutics Performance
Assessing NLS Pharmaceutics' fundamental ratios provides investors with valuable insights into NLS Pharmaceutics' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the NLS Pharmaceutics is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
NLS Pharmaceutics AG, a biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company was incorporated in 2015 and is based in Zurich, Switzerland. Nls Pharmaceutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 6 people.Things to note about NLS Pharmaceutics performance evaluation
Checking the ongoing alerts about NLS Pharmaceutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for NLS Pharmaceutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| NLS Pharmaceutics had very high historical volatility over the last 90 days | |
| NLS Pharmaceutics may become a speculative penny stock | |
| NLS Pharmaceutics has a very high chance of going through financial distress in the upcoming years | |
| NLS Pharmaceutics AG currently holds 1.63 M in liabilities. NLS Pharmaceutics has a current ratio of 0.58, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about NLS Pharmaceutics' use of debt, we should always consider it together with its cash and equity. | |
| Net Loss for the year was (12.17 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| NLS Pharmaceutics AG currently holds about 1.35 M in cash with (9.68 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.08. | |
| Roughly 41.0% of the company outstanding shares are owned by corporate insiders |
- Analyzing NLS Pharmaceutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether NLS Pharmaceutics' stock is overvalued or undervalued compared to its peers.
- Examining NLS Pharmaceutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating NLS Pharmaceutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of NLS Pharmaceutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of NLS Pharmaceutics' stock. These opinions can provide insight into NLS Pharmaceutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for NLS Stock Analysis
When running NLS Pharmaceutics' price analysis, check to measure NLS Pharmaceutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NLS Pharmaceutics is operating at the current time. Most of NLS Pharmaceutics' value examination focuses on studying past and present price action to predict the probability of NLS Pharmaceutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NLS Pharmaceutics' price. Additionally, you may evaluate how the addition of NLS Pharmaceutics to your portfolios can decrease your overall portfolio volatility.